-
1 Comment
Tsumura & Co is currently in a long term downtrend where the price is trading 2.2% below its 200 day moving average.
From a valuation standpoint, the stock is 96.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.4.
Tsumura & Co's total revenue rose by 3.2% to $35B since the same quarter in the previous year.
Its net income has increased by 13.3% to $5B since the same quarter in the previous year.
Finally, its free cash flow grew by 59.3% to $-245M since the same quarter in the previous year.
Based on the above factors, Tsumura & Co gets an overall score of 4/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | JP3535800001 |
| PE Ratio | 8.29 |
|---|---|
| Target Price | 4138.3335 |
| Beta | -0.05 |
| Dividend Yield | 3.8% |
| Market Cap | 264B |
Tsumura & Co. engages in the production and sale of Kampo extract intermediates and granular Kampo formulations in Japan and internationally. The company offers products for female problems, proneness to fatigue, skin problems, gastrointestinal problems, obesity, constipation and hemorrhoids, as well as body aches, children's sickness, stress, urinary problems, and cold, cough, and nasal and throat inflammation symptoms. It also offers over-the-counter Kampo medicines. The company was founded in 1893 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4540.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
